Praxis Precision Medicines (PRAX) EBIT Margin (2023 - 2024)
Praxis Precision Medicines (PRAX) posted quarterly EBIT Margin of 856.97% for Q4 2024, up 454225.0% year-over-year from N/an in Q1 2024, and up 95.45% quarter-over-quarter from 18819.54% in Q3 2024.
Praxis Precision Medicines (PRAX) EBIT Margin (2023 - 2024) Analysis & Trends
Praxis Precision Medicines' EBIT Margin history runs 2 years deep, the most recent figure standing at 856.97% for Q4 2024.
- In Q4 2024, EBIT Margin rose 454225.0% year-over-year to 856.97%; the TTM figure through Sep 2025 stood at 3927.51% (up 629149.0% YoY), while the FY2024 annual figure was 2340.29%, up 282412.0% from the prior year.
- EBIT Margin for Q4 2024 stood at 856.97%, up from 18819.54% in the prior quarter.
- The five-year high for EBIT Margin was 856.97% in Q4 2024, with the low at 18819.54% in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.46 Bn | 131.61 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 85.04 Bn | 77.05 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 64.55 Bn | 59.36 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 59.56 Bn | 54.42 Bn | 52.00 Mn | -562.07% |
| 5 | BeOne Medicines | 41.90 Bn | 36.80 Bn | 1.53 Bn | 19.06% |
| 6 | Alnylam Pharmaceuticals | 31.69 Bn | 28.38 Bn | 992.69 Mn | 17.93% |
| 7 | Royalty Pharma | 27.45 Bn | 26.61 Bn | - | 19.75% |
| 8 | BioNTech SE | 27.40 Bn | 9.01 Bn | 668.28 Mn | -35.57% |
| 9 | Insmed | 26.70 Bn | 25.54 Bn | 358.27 Mn | -0.36% |
| 10 | Praxis Precision Medicines | 10.83 Bn | 10.07 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -856.97% |
| Sep 30, 2024 | -18,819.54% |
| Jun 30, 2024 | -10,500.84% |
| Mar 31, 2024 | -9,718.33% |
| Dec 31, 2023 | -5,399.22% |
| Sep 30, 2023 | -5,452.14% |
| Jun 30, 2023 | -4,476.31% |
| Mar 31, 2023 | -5,577.01% |